| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP > 100 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
Cilazapril: n=94(67 males,27 females); mean age=52.4(8.1) years; baseline BP not reported;
Placebo: n=46(28 males,18 females); mean age=54.1(7.0) years; baseline BP not reported |
| Interventions |
Cilazapril 2.5 mg once daily;
Cilazapril 5 mg once daily;
Placebo;
taken at approximately 12 PM before meal |
| Outcomes |
Mean change from baseline in trough sitting DBP using mercury sphygmomanometer;
WDAE |
| Notes |
SBP change not reported; DBP change reported; SD of change not reported, endpoint SBP/DBP and SD not reported; imputed overall trial mean SD of change for DBP; baseline BP not reported; BP data from Figure 1, p. 119; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
